

SCA1 – Kirjallisuusviitteet

Orr HT et al: Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4: 221 – 226, 1993

Giunti P et al.: The trinucleotide repeat expansion on chromosome 6p (SCA1) in autosomal dominant cerebellar ataxias. Brain 117: 645 – 649, 1994

Genis D et al., Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)_n expansion and early premonitory signs and symptoms. Neurology 45: 24 – 30, 1995

Schöls L et al.: Spinocerebellar ataxia type 1: clinical and neurophysiological characteristics in German kindreds. Acta Neurol Scand 92: 478 – 485, 1995

Bürk K et al.: Autosomal dominant cerebellar ataxia type I. Clinical features and MRI in families with SCA1, SCA2 and SCA3. Brain 119: 1497 – 1505, 1996

Kaakkola S ja Rinne R: Ataksiat ja niiden erotusdiagnostiikka (katsaus). Duodecim 113: 1773 – 1782, 1997

Cummings CJ et al.: Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genetics 19: 148 – 153, 1998

Grewal RP et al.: Clinical and genetic analysis of a distinct autosomal dominant spinocerebellar ataxia. Neurology 51: 1423 – 1426, 1998

Moseley ML et al.: Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 51: 1666 – 1671, 1998

Rivaud-Pechoux S et al.: Eye movement abnormalities correlate with genotype in autosomal dominant cerebellar ataxia type I. Ann Neurol 43: 297 – 302, 1998

Schöls L et al.: Sleep disturbance in spinocerebellar ataxias. Is the SCA3 mutation a cause of restless legs syndrome? Neurology 51: 1603 – 1607, 1998

Trojano I et al., Determinants of cognitive disorders in autosomal dominant cerebellar ataxia type 1. J Neurol Sci 157: 162 – 167, 1998

Vig PJS et al: Reduced immunoreactivity to calcium-binding proteins in Purkinje cells precedes onset of ataxia in spinocerebellar ataxia-1 transgenic mice. Neurology 50: 106 – 113, 1998

Duyckaerts C et al., Nuclear inclusion in spinocerebellar ataxia type 1. Acta Neuropathol (Berl.) 97: 201 – 207, 1999

Orr T and Klockgether T: Spinocerebellar Ataxia 1. Kirjassa: Handbook of Ataxia Disorders, 343 - 361. Toim. Klockgether T, Marcel Dekker Inc., New York-Basel, 2000

Storey E et al., Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 95: 351-357, 2000

Srivastava AK et al., Molecular and clinical correlation in five Indian families with spinocerebellar ataxia 12. Ann Neurol 50: 796-800, 2001

Bryer A et al., The hereditary adult-onset ataxias in South Africa. J Neurol Sci 216: 47-54, 2003

Bürk K et al., Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. *J Neurol* 250: 207 – 211, 2003

Emami ES et al., Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. *Neuron* 38: 375 – 387, 2003

Nagaoka U et al., Attenuated nuclear shrinkage in neurones with nuclear inclusions of SCA1 brains. *J Neurol Neurosurg Psychiatry* 74: 797 – 6001, 2003

Brusco A et al., Molecular genetics of hereditary spinocerebellar ataxia. Mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. *Arch Neurol* 61: 727 – 733, 2004

Guerrini L et al., Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. *Brain* 127: 1785 – 1795, 2004

Park Y et al., Proteasome function is inhibited by polyglutamine-expanded Ataxin-1, the SCA1 gene product. *Mol Cell* 19, 23 – 30, 2004

Serra HG et al., Gene profiling links SCA1 pathophysiology to glutamate signalling in Purkinje cells of transgenic mice. *Hum Mol Genet* 13: 2535 – 2543, 2004

Tsai C-C et al., Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptor. *PNAS* 101, 4047 – 4052, 2004

van de Warrenburg BPC et al., Peripheral nerve involvement in spinocerebellar ataxias. *Arch Neurol* 61: 257 – 261, 2004

Xia H et al., RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. *Nat Med* 10: 816 – 820, 2004

Zu T et al., Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. *J Neurosci* 24: 8853 – 8861, 2004

Gerwig M et al., Timing of conditioned eyeblink responses is impaired in cerebellar patients. *J Neurosci* 25: 3919 – 3931, 2005

Irwin S et al., RNA association and nucleocytoplasmic shuttling by ataxin-1. *J Cell Sci* 118: 233 – 242, 2005

Juvonen V et al. The occurrence of dominant spinocerebellar ataxias among 251 Finnish ataxia patients and the role of predisposing large normal alleles in a genetically isolated population. *Acta Neurol Scand* 111: 154 – 1562, 2005

Kaytor MD et al., A cell-based screen for modulators of ataxin-1 phosphorylation. *Hum Mol Genet* 14: 1095 – 1105, 2005

Rakowicz M et al., Spinocerebellar ataxias type 1 and 2: comparison of clinical, electrophysiological and magnetic resonance evaluation (artikkeli puolaksi). *Neurol Neurochir Pol* 39: 263 – 275, 2005

Tanaka M et al., A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. *J Mol Med* 83: 343 – 352, 2005

van de Warrenburg BPC et al., Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch-Frech cohort. *Ann Neurol* 57: 505 – 512, 2005

Wüllner U et al., Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3 and 6. Arch Neurol 62: 1280 – 1285, 2005

Dragasevic NT et al., Frequency analysis and clinical characterization of different types of spinocerebellar ataxia in Serbian patients. Mov Disord 21(2): 187 – 191, 2006